Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ADK | P55263 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4973147 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2KDM4EPOLBMAPTLMNA | |
| SCHEMBL23908005 | 0.79 | KDM4E (0.52) | SMN1; SMN2KDM4EPOLBMAPTLMNA | |
| SCHEMBL21834739 | 0.79 | CTSK (0.43) | SMN1; SMN2KDM4EPOLBLMNAALDH1A1 | |
| SCHEMBL13828583 | 0.79 | SMN1; SMN2 (0.48) | SMN1; SMN2POLBMAPTALDH1A1L3MBTL1 | |
| SCHEMBL7930954 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2KDM4EPOLBMAPTLMNA | |
| SCHEMBL21834760 | 0.77 | KDM4E (0.44) | SMN1; SMN2KDM4EMAPTALDH1A1PIK3CA | |
| SCHEMBL2811716 | 0.76 | KMT2A (0.46) | SMN1; SMN2KDM4EPOLBMAPTLMNA | |
| SCHEMBL24537180 | 0.76 | SMN1; SMN2 (0.46) | SMN1; SMN2KDM4EPOLBMAPTALDH1A1 | |
| SCHEMBL29680060 | 0.76 | SMN1; SMN2 (0.46) | SMN1; SMN2KDM4EPOLBMAPTALDH1A1 | |
| SCHEMBL14849909 | 0.75 | SMN1; SMN2 (0.42) | SMN1; SMN2KDM4EPOLBMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034311-B2 | Pyridin-2(1 H)-one derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-05-19 | — | — | US | disclosed |
| US-20140271543-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-09-18 | — | — | US | disclosed |
| EP-2739616-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | Almirall, S.A. (ES) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013017461-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-02-07 | — | — | WO | disclosed |
| EP-2152702-B1 | AMINO-THIAZOLYL- PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2011-08-24 | — | — | EP | disclosed |
| US-20100204231-A1 | AMINO-THIAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2010-08-12 | — | — | US | disclosed |
| EP-2152702-A1 | AMINO-THIAZOLYL- PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008135786-A1 | AMINO-THIAZOLYL- PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008132502-A1 | PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204231-A1 | AMINO-THIAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | THPO, TYMP, TPMT | SMN1; SMN2 3646/4885KDM4E 2014/4885POLB 509/4885 |
| US-20140271543-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | SMN1; SMN2 3968/4885KDM4E 947/4885POLB 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.